Premium
The phosphoinositide 3‐kinase/Akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines
Author(s) -
Plo I.,
Bettaïeb A.,
Payrastre B.,
Mansat-De Mas V.,
Bordier C.,
Rousse A.,
Kowalski-Chauvel A.,
Laurent G.,
Lautier D.
Publication year - 1999
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(99)00631-6
Subject(s) - daunorubicin , phosphoinositide 3 kinase , protein kinase b , wortmannin , myeloid leukemia , ly294002 , cancer research , ceramide , pi3k/akt/mtor pathway , microbiology and biotechnology , leukemia , biology , apoptosis , chemistry , signal transduction , biochemistry , immunology
Daunorubicin induces apoptosis in myeloid leukemia cells by activation of neutral sphingomyelinase and ceramide generation occurring 4–10 min after daunorubicin addition. We show here that daunorubicin is able to increase the phosphoinositide 3‐kinase activity and enhance intracellular phosphoinositide 3‐kinase lipid products prior to ceramide generation. Daunorubicin activates Akt, a downstream phosphoinositide 3‐kinase effector. Interestingly, the phosphoinositide 3‐kinase inhibitors wortmannin and LY294002 accelerate daunorubicin‐induced apoptosis in U937 cells. The phosphoinositide 3‐kinase/Akt pathway has been involved in cell survival following serum deprivation, tumor necrosis factor α, anti‐Fas and UV radiations. Our results suggest that anti‐tumor agents such as daunorubicin may also activate anti‐apoptotic signals that could contribute to drug resistance.